Senior Research Fellow. Statistician. Novel trial methods. Former Wellcome Trust & NIHR DR fellow. Views are my own. RT≠ENDORSEMENT 🇿🇼 🇬🇧
Sheffield, England
Joined July 2010
- Tweets38.1K
- Following2.3K
- Followers2.5K
- Likes38.9K
Pinned Tweet
Canner (1983) ... “decision-making in clinical trials is complicated & often protracted... no single statistical decision rule or procedure can take the place of well-reasoned consideration of all aspects of the data by a group of concerned, competent, & experienced persons...”
Munya Dimairo retweeted
I do these every morning with a cup of tea out of my positive mindset cup. Been doing this for 2 months now. You don’t have to believe it all at the start!!! It’ll come
Munya Dimairo retweeted
🚨 EXC: Nottingham hospital launches urgent investigation into hip fracture deaths as its mortality rate hits 50% more than national average - the problem is linked to long delays for emergency surgery according to internal documents.
Full story: thetimes.com/article/b5bc397…
Munya Dimairo retweeted
This one's for you, dad. @NEJM nejm.org/doi/full/10.1056/NE…
Munya Dimairo retweeted
Randomised controlled trials (RCTs) remain the most reliable method for controlling confounding and selection bias when evaluating interventions for clinical use.
A new Comment explores the need for more head-to-head RCTs comparing treatments already in common use: spkl.io/60147kyfy
Munya Dimairo retweeted
🎉 Delighted to finally hold the physical copy of my book, Practical Statistics in Medicine with R: Understanding Fundamental Concepts through Examples.
📓 For orders: routledge.com/9781032602080
Munya Dimairo retweeted
Most tax calculators tell you how much tax you pay *now*. Ours also shows how much tax you'll pay on your next £1. Your marginal rate.
We'll be publishing straight after the Budget. But here's a preview - I'd love to get feedback.
taxpolicy.org.uk/uk-tax-calc…
Munya Dimairo retweeted
Have you ever seen a waterfall going up? 🌊🌬️
Kinder Downfall in the Peak District on a windy day When the winds hit the plateau, they blow the falling water straight back up over the cliffs, creating this unbelievable upside-down waterfall effect.
#KinderDownfall #PeakDistrict
Munya Dimairo retweeted
The UK launched the AI Biosecurity Lab: £100M public funding plus up to £200M from OpenAI and Anthropic, to spot biological threats earlier and speed up vaccines and treatments.
Europe has world-class biology. Let's put frontier AI right next to it. 👇🏻
gov.uk/government/news/intro…
Munya Dimairo retweeted
There are currently no approved therapies available for Sjögren’s disease, and trials of multiple biologic and targeted approaches have been negative or inconclusive. Research findings are summarized in a new Quick Take video. nej.md/4BcjQxL
ALT Illustration showing a patient with Sjögren’s disease and ianalumab, an IgG1 monoclonal antibody that depletes B cells and blocks B-cell activation and survival through the BAFF receptor.
Munya Dimairo retweeted
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment. trib.al/IoxKBxQ
Munya Dimairo retweeted
Estimating Marginal Odds Ratios for Cluster Randomized Trials: The Cluster‐Level GLM. Jennifer A. Thompson, Brennan C. Kahan, Andrew Copas. Statistics in Medicine. onlinelibrary.wiley.com/doi/…
Munya Dimairo retweeted
📣 We’re looking for a Chair for our Invention for Innovation (i4i) Product Development Awards (PDA) Funding Committee!
Are you an experienced medtech or life sciences industry professional with a passion for health innovation? This could be an opportunity to help shape the future of healthcare technology development for the NHS.
As Chair, you will lead one of our i4i funding committees, contribute to the strategic development of the programme and strengthen our links with industry.
Interested? Apply now ➡️ nihr.ac.uk/honorary-and-spec…
⏰ Closes on 23 November 2026
#HealthInnovation #MedTech #LifeSciences #ResearchFunding
ALT An announcement graphic with a light blue background, featuring text on the left and curved blue abstract shapes on the right. In the top left, the logo reads "NIHR | National Institute for Health and Care Research". Below the logo, dark blue text reads: "Honorary and specialty role Chair of the Invention for Innovation (i4i) Product Development Awards (PDA) Funding Committee Closing on 23 November 2026" A yellow button at the bottom left reads "Apply now" in dark blue text. The right side features two large, curved, overlapping arch shapes in shades of blue. In the bottom right corner, a small logo reads "20 Years" in dark blue, with the "0" styled as a blue and red circle.
Munya Dimairo retweeted
#ESMO26: The embargo on LBA1, “INTerpath-001: Phase 3 study of the mRNA-based individualised neoantigen therapy intismeran autogene plus pembrolizumab versus pembrolizumab alone for adjuvant treatment of resected stage IIB-IV melanoma”, has been breached. As the data are now publicly available, ESMO has released the information contained in the abstract and has lifted the embargo on the full dataset.
Munya Dimairo retweeted
Big News! CDER's Accelerating Rare disease Cures (ARC) Program released its 2026 Annual Report, highlighting the Program’s success in advancing rare disease drug development for the ~30M Americans living with a rare disease. Read it here: fda.gov/drugs/drug-alerts-an…
Munya Dimairo retweeted
Providing authors of randomised controlled trials with a SPIRIT based template during manuscript revision modestly improved the completeness of reporting in the trial protocols without extending revision times., finds new #BMJResearch
bmj.com/content/395/bmj-2026…
Munya Dimairo retweeted
Almost one million African healthcare workers, including doctors, are unemployed despite the continent needing six million more staff to meet health needs, experts told an event at the World Health Summit in Berlin
bmj.com/content/395/bmj-2026…
Munya Dimairo retweeted
National recall of GLP-1 drug (tirzepatide) made by a US compounding pharmacy because it puts patients at risk, according to FDA
usatoday.com/story/money/con…
Munya Dimairo retweeted
Should a pharmaceutical company invest in a dedicated statistical methodology group?
On this week's "In the Interim…", Scott Berry talks with Jenny Devenport and Kaspar Rufibach of Merck Group, co-authors of the paper "Statistical Methodology Groups in the Pharmaceutical Industry," and May Mo of Amgen, a co-author of a US commentary on it.
Highlights from the conversation:
✅️ Why a new method adds little until it is published, built into software, and scaled
✅️ How new mechanisms of action are pushing trial design beyond the t-test and log-rank test
✅️ Keeping methodologists and project statisticians working as one team
✅️ How one better phase 3 decision can pay for a methods group
✅️ Giving leadership design options, risks, and trade-offs instead of a single answer
The full episode is live now: berryconsultants.com/resourc…
Munya Dimairo retweeted
We applaud the UK’s MHRA for implementing these long-overdue measures to inform patients of the risks of suicidality when initiating antidepressant treatment or adjusting dosages, as well as the risk of persistent sexual dysfunction.
We urge the U.S. @FDA to follow suit and, alongside other @HHSGov agencies, prioritize helping those who have already been harm.
Years-long sufferers of PSSD @PSSDNetwork and protracted withdrawal deserve acknowledgment, answers, and, most importantly, effective treatments.
The MHRA is introducing a series of new measures to strengthen how risks associated with antidepressant medicines are communicated to patients, carers and healthcare professionals. Read the full drug safety update here: brnw.ch/21x6qlr
